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Abstract
Among the three isoforms encoded by Rtn4, Nogo-A has been intensely investigated as a central nervous system
inhibitor. Although Nogo-A expression is increased in muscles of patients with amyotrophic lateral sclerosis, its role in
muscle homeostasis and regeneration is not well elucidated. In this study, we discovered a significant increase in
Nogo-A expression in various muscle-related pathological conditions. Nogo−/− mice displayed dystrophic muscle
structure, dysregulated muscle regeneration following injury, and altered gene expression involving lipid storage and
muscle cell differentiation. We hypothesized that increased Nogo-A levels might regulate muscle regeneration.
Differentiating myoblasts exhibited Nogo-A upregulation and silencing Nogo-A abrogated myoblast differentiation.
Nogo-A interacted with filamin-C, suggesting a role for Nogo-A in cytoskeletal arrangement during myogenesis. In
conclusion, Nogo-A maintains muscle homeostasis and integrity, and pathologically altered Nogo-A expression
mediates muscle regeneration, suggesting Nogo-A as a novel target for the treatment of myopathies in clinical
settings.
Introduction
Muscular dystrophies are a group of genetic muscle
disorders that cause defective muscle fiber function due to
the weakening and breakdown of muscle fibers as a result
of inflammation accompanied with abrogated muscle
regeneration. Duchenne muscular dystrophy (DMD), the
most common form of muscular dystrophy, is severe
myopathy associated with an abrogated dystrophin gene,
which results in muscle membrane frailty associated with
increased pro-inflammatory cytokine levels, mitochon-
drial dysfunction, and impaired satellite cell polarity1–4.
Following injury, satellite cells transform to committed
myoblasts and ultimately differentiate into myofibers
during myogenesis, a multistep process including trans-
formation of satellite cells into myoblasts, differentiation
into fusion-competent myoblasts, and their fusion into
multinucleated myotubes5,6. Myogenesis is regulated by
the synchronized actions of the myogenic regulatory
factors myogenic factor 5, MyoD, and myogenin, and
results in the expression of muscle-specific genes7,8.
During differentiation, the Pax3 and Pax7 expression
levels are downregulated, although satellite cells retain
Pax7 expression during quiescence9–11.
The neurite outgrowth inhibitor Nogo, also known as
reticulon 4, is encoded by Rtn4. Independently cloned by
three groups12–14, Rtn4 complementary DNA (cDNA)
was found to generate three Nogo isoforms, Nogo-A,
Nogo-B, and Nogo-C, by alternative splicing or distinctive
promoter usage15,16. Although mainly localized to the
endoplasmic reticulum (ER), Nogo has also been observed
on the cell surface17. Nogo-A, the largest Nogo isoform,
which also carries an inhibitor region named Δ20, is a
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potent neurite growth inhibitor in the central nervous
system (CNS)14,15. Nogo-A is expressed in the brain,
spinal cord, eye, and skeletal muscle18, and most of our
knowledge on Nogo-A concerns its function as a neurite
outgrowth inhibitor in the CNS13,19. On the surface of
cells, Nogo-A acts via its receptors Nogo-66 receptor 1,
sphingosine-1-phosphate receptor (S1PR) 2, and myelin-
associated glycoprotein. Nogo isoforms binds Nogo-66
receptor 1 and inhibits neurite growth via the Rho/Rho-
associated kinase signaling pathway14,18,20,21. However,
the mechanisms underlying the role of Nogo-A in muscle
regeneration and myogenesis in skeletal muscle remain
elusive.
In the present study, we also elucidate the role of Nogo in
the regulation of muscle homeostasis, muscle differentia-
tion, and adipocyte differentiation based on the muscle
transcriptome profiles of Nogo+/+ and Nogo−/− mice. We
use a muscle-injury model in Nogo−/− mice to examine
Nogo-A involvement in muscle regeneration and further
demonstrate the potent myogenic function of Nogo-A in
myoblast differentiation using muscle lineage cells,
including C2C12 cells and induced muscle stem cells
(iMSCs). Our findings suggest that the expression of Nogo-
A is altered in the skeletal muscle during pathological
processes, and that Nogo-A serves a critical function in
muscle regeneration and maintenance of muscle integrity.
Results
Nogo expression is altered in the muscle tissue of patients
with myopathies
Muscle tissue samples from patients with different
myopathies, including DMD and inflammatory myopathy,
exhibited typical histopathological features of muscle
degeneration including damaged myofiber structure,
inflammatory cell infiltration, and fibrosis resulting from
incomplete muscle regeneration (Fig. 1A). Thus, we
examined the transcriptional expression levels of Nogo
isoforms and myogenic factors in muscle tissues from
patients with myopathies including DMD and inflamma-
tory myopathy, which revealed that the levels of Nogo
isoforms were significantly altered in the muscle samples
of patients with myopathies (Fig. 1B). Specifically,
although the level of Nogo-B in myopathic tissues was
comparable to that in normal muscle tissues, the level of
Nogo-A was dramatically elevated and the level of Nogo-
C was significantly reduced in the myopathic tissues
compared with the normal tissues (Fig. 1B). The tran-
script levels of Pax7, a satellite cell marker, and myogenic
factors including MyoD and myogenin were upregulated
in the myopathic tissues compared to the normal tissues
(Fig. 1B), and the increased Nogo-A and myogenin tran-
script levels were associated with an elevation in the
protein levels of Nogo-A and myogenin in the myopathic
tissues (Fig. 1C, D).
The expression levels of Nogo and myogenic factors are
altered in animal models of muscle disorders
The muscles of mdx mice, the animal model of human
DMD, showed significantly elevated mRNA levels of
Nogo-A (Fig. 2A), MyoD, and myogenin (Fig. 2B), and a
reduced Nogo-C mRNA level (Fig. 2A) compared with the
wild-type (WT) mice. These results were consistent with
our analyses in human muscle samples from myopathies
(Fig. 1B). The observed upregulation in Nogo-A and
Myod transcript levels was accompanied by increases in
their protein levels (Fig. 2C, D). Dasarathy et al.22 have
demonstrated a relationship between skeletal muscle loss
and alcoholic liver disease (ALD); thus, we also analyzed
the skeletal muscle in a mouse model of ALD as a myo-
pathy model associated with chronic liver dysfunction. In
current study, the mouse ALD model successfully exhib-
ited liver pathology including hepatomegaly, determined
by the ratio of liver weight to body weight (Fig. S1A), and
elevated levels of plasma aspartate aminotransferase
(AST) and alanine aminotransferase (ALT) (Fig. S1C)
compared to the control mice. Therefore, the elevated
plasma ALT and AST levels in ALD mice suggest liver
dysfunction as well as muscle damage (Fig. S1C). The
skeletal muscle tissues of the ALD mice exhibited upre-
gulated Nogo-A and reduced Nogo-C mRNA levels
compared to the controls (Fig. 2E); the tissues also
showed elevated levels of myogenin and Pax7 (Fig. 2F),
suggesting increased numbers of committed Pax7+
satellite cells and myogenin-positive myoblasts.
Acute muscle injury induced by notexin injection was
associated with a dramatic increase in Nogo-A and a
significant reduction in Nogo-C (Fig. 2G), as well as sig-
nificant upregulation of Myod and myogenin (Fig. 2H). In
these animals, the number of Pax7+ committed satellite
cells was not altered but the MYH2 expression was dra-
matically downregulated, indicating structural muscle
damage (Fig. 2H).
Muscle lacking Nogo exhibits abnormal structure and
impaired regeneration following notexin-induced muscle
injury
Although the Nogo-A+/+ muscles exhibited well-
structured muscle fibers and the absence of inflamma-
tory cell infiltration, the Nogo−/− muscles displayed
defective myofibers and exhibited immune cell infiltration
(Fig. 3A, right panel, arrow). Notexin-induced muscle
damage results in inflammation at the site of injection
3 days post injury, with the completion of regeneration
28 days post injury23. The notexin-injured muscles from
Nogo-A+/+ mice exhibited centrally nucleated fibers
indicating regenerating myofibers and increased infiltra-
tion of inflammatory cells between the fibers at 8 days
post injury (Fig. 3A, left). In contrast, the muscles from
notexin-injured Nogo−/− mice displayed a higher number
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of regenerated myofibers and inflammatory cells, sug-
gesting the susceptibility of Nogo-deficient muscles to
injury (Fig. 3A, right). In addition, myofibers with defec-
tive regeneration (Fig. 3A, right, arrow) and increased
fibrotic cells (Fig. 3A, right, arrowhead) in injured Nogo−/−
muscles represented the atrophy phenotype.
Absence of Nogo abrogates muscle differentiation and
enhances fat cell differentiation and lipid metabolism-
related gene expression
Comparison of the mRNA expression profiles between
the two groups identified 703 differentially expressed
genes (DEGs), including 355 genes that were upregulated
and 348 genes that were downregulated in the Nogo−/−
muscles compared to the Nogo-A+/+ muscles (Table S1).
To investigate potential cellular processes affected by
Nogo, we conducted an enrichment analysis of Gene
Ontology biological processes (GOBPs) and Gene
Ontology molecular functions (GOMFs) using the
DAVID software (Table S2). The upregulated genes in
Nogo−/− muscles were mainly involved in fat cell devel-
opment; specifically, brown and white fat cell differ-
entiation and lipid metabolism via the fatty acid metabolic
process, the insulin receptor signaling pathway, and the
peroxisome proliferator-activated receptor signaling
pathway (Fig. 3B, C). The downregulated genes were
Fig. 1 Altered expression of Nogo and myogenic factors in muscles under pathological or abnormal physiological states. A Hematoxylin/
eosin staining of muscle biopsy samples from patients with Duchenne muscular dystrophy (DMD) and inflammatory myopathies and normal
subjects. Scale bar= 100 µm. B Muscle mRNA samples from normal human subjects (n= 5) and patients with myopathy (n= 8–10) were evaluated
by quantitative reverse-transcription PCR (qRT-PCR). Mean ± SEM. **p < 0.01. C Western blot (WB) analysis of indicated proteins in muscles tissue
samples from normal subjects (n= 3) and myopathic patients (n= 4). Molecular weights (kDa) are indicated. D Quantitative assessment of band
intensity (C) using the NIH ImageJ software. Mean ± SEM. *p < 0.05.
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mainly involved in cytoskeletal organization and included
actin filament-base processing, actin cytoskeleton orga-
nization, actin binding, and muscle development via reg-
ulation of muscle hypertrophy, skeletal muscle adaptation,
and cell differentiation (Fig. 3B). The GOMFs enriched by
the downregulated genes included S1PR activity, which
can induce myogenesis24 (Fig. 3C).
The TF enrichment analysis to uncover potential TFs
regulated by Nogo (Fig. 3D and Table S3) revealed 17
major TFs regulating several DEGs. Among these, Nogo
Fig. 2 Altered expression of Nogo and myogenic factors in animal myopathy models. A, B qRT-PCR analysis for indicated genes in muscle
samples from 12-week-old wild-type (WT) (n= 4) and mdx (n= 3) mice. Mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. C WB analysis of indicated
proteins in muscle extracts from 12-week-old WT (n= 4) and mdx (n= 3) mice. Molecular weights (kDa) are indicated. D Quantitative assessment for
protein (C) using the NIH ImageJ software. Mean ± SEM. **p < 0.01. E, F qRT-PCR analysis for indicated genes in muscle samples from control (Con,
n= 6) mice in a model of alcoholic liver disease (ALD) (n= 8). Mean ± SEM. *p < 0.05. G, H qRT-PCR analysis for indicated genes in muscle samples
from control (Con, n= 3) and notexin-injured mice (8-week-old C57BL/6, 50 ng/gastrocnemius, 3 days post injury, n= 3). Mean ± SEM. *p < 0.05, **p
< 0.01, ***p < 0.001.
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knockout (KO) upregulated four TFs known to regulate
fat cell development, Cebpa, Cebpb, Cebpd, and
Pparg25,26, but downregulated Myod1, a master TF for
muscle development27 (Fig. 3D), suggesting that these TFs
act downstream from Nogo and contribute to the
attenuation of myotube development.
Finally, we built a network model describing the genes
associated with the identified GOBPs and major TFs as
indicated above to understand the functions of the DEGs
and the five major TFs in attenuation of myotube devel-
opment, which showed that Nogo KO downregulated
Wnt signaling, indicated by the downregulation ofWnt5a,
Fzd9, and Six1, resulting in decreased activation of
Myod128 (Fig. 3E, left). Consistent with this finding,
negative regulators of Myod1, including Id1/3, and the
upstream TFs Cebpa, Cebpb, Cebpd, and Pparg were
Fig. 3 Cellular processes affected by Nogo deficiency, and muscle physiology of notexin-induced Nogo−/− mice. A Representative images of
hematoxylin/eosin stained non-injured control (Con, n= 5) and notexin-injured (500 ng/gastrocnemius, n= 5) muscles from Nogo+/+ or Nogo−/−
mice. Short and long arrows indicate defective and regenerating myofibers, respectively. Arrowheads mark fibrotic cells. Scale bar= 50 µm. Gene
Ontology biological processes (GOBPs) (B) and gene Ontology molecular functions (GOMFs) (C) represented by genes up- and downregulated by
Nogo knockout. Enrichment significance was determined via p-values calculated with DAVID is displayed as −log10(P). P-values for up- and
downregulated GOBPs or GOMFs are denoted using orange or light blue bars, respectively. p < 0.05. D Major transcription factors (TFs) that regulate a
high number of differentially regulated genes (DEGs). Four upregulated TFs and one downregulated TF in Nogo−/− mice are labeled in orange and
light blue, respectively. E Model network describing potential roles of Nogo in the regulation of myogenesis. Node colors represent upregulation
(orange) and downregulation (blue) of the corresponding genes by the Nogo knockout. Arrows and suppression symbols denote activation and
inhibition, respectively, based on the KEGG pathway database. Solid and dotted lines represent direct and indirect reactions, respectively, and gray
lines represent protein–protein interactions between the connected nodes. The color bar represents gradient of log2 fold changes, log2(FC),
between the Nogo−/− and WT muscle tissues. F Network model for circadian rhythm regulation in Nogo−/− mouse. Node colors represent
upregulation (red) and downregulation (blue) of the corresponding genes by Nogo knockout. Arrows and suppression symbols denote activation
and inhibition, respectively, based on the KEGG pathway database. Solid and dotted lines represent direct and indirect reactions, respectively, and
gray lines represent protein–protein interactions between the connected nodes. The color bar represents gradient of log2(FC) between the Nogo−/−
and WT muscle tissues. G, H qRT-PCR analysis for indicated genes in muscle samples from 8- and 70-week-old Nogo+/+ (n= 4) and Nogo−/− (n= 3)
mice. Mean ± SEM. *p < 0.05, **p < 0.01.
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upregulated by Nogo KO (Fig. 3E, bottom). The network
model also indicated that Nogo KO altered the mRNA
expression levels of Slc8a3, Cacna1g, and Sphk2, which
are involved in decreasing the amount of cytosolic cal-
cium (Fig. 3E, right). Consistent with this finding, Nogo
KO further downregulated Calm1 and Adcy9a in the
downstream calcium signaling pathway, and S1pr3/4,
Pik3ca, and Prkcd in the downstream sphingosine-1
phosphate phosphatidylinositol 3-kinase pathway (Fig.
3E, middle), resulting in decreased activation of cytoske-
leton reorganization observed by downregulation of
Marcks, Ppp1r14a, and Acta2. These data suggest that
Nogo positively regulates Wnt, calcium, MyoD1, and S1P
phosphatidylinositol 3-kinase signaling pathways, and
negatively regulates insulin signaling, Cebpa, Cebpb,
Cebpd, and Pparg, to coordinate myogenesis regulation.
Interestingly, genes related to circadian rhythm were
significantly represented in both the up- and down-
regulated gene groups in the Nogo−/− muscles (Fig. 3F).
To elucidate the potential circadian clock activity result-
ing from Nogo KO, we mapped the identified DEGs to the
Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathway database and identified the core clock compo-
nents Cry1, Cry2, Per1, Per2, Per3, Bhlhe40, Bmal1,
Npas2, and Clock as DEGs in the circadian rhythm
pathway. Specifically, the CLOCK/BMAL1 inhibitors
Cry2, Per1, Per2, Per3, and Bhlhe40 were upregulated and
the CLOCK/BMAL1 components Bmal1, Npas2, and
Clock were downregulated. These clock components are
known to regulate myogenesis29–32. The CLOCK/BMAL1
elements Bmal1, Npas2, and Clock bind to the Myod1
enhancer to induce Myod1 expression (Fig. 3E, left)29,30.
Cry1 and Cry2 play opposing roles in myogenic differ-
entiation: Cry1 knockdown promotes myoblast differ-
entiation, which is inhibited by Cry2 knockdown (Fig. 3E,
middle)32. In contrast, Bhlhe40 regulates adipogenic dif-
ferentiation by interacting with Cebpb (Fig. 3F, top)31.
These models suggest that Nogo-A regulates myogenesis
through the control of circadian clock gene expression.
Further, muscles from 70-week-old mice were analyzed to
delineate Nogo activity in circadian regulation and mus-
cular fat cell deposition. As seen in Figs. 3G and 3H, the
downregulation of Bmal1 and Npas2 was enhanced in
aged Nogo−/− muscles and was accompanied by an
increase in Cebpa, suggesting that Nogo modulates fat
deposition in muscle via circadian clock regulation.
Nogo-A is highly expressed during late differentiation in
C2C12 cells and is related to the expression of myogenic
factors
Based on our observation that Nogo-A levels were
increased under pathological conditions, we assessed the
role of Nogo-A during myogenesis in C2C12 mouse
myoblasts. During early differentiation, the expression
levels of Pax7, a quiescent satellite cell marker, and MyoD,
an early myogenic differentiation marker, were significant
and Nogo-A expression was observed in Pax7− and
MyoD+ cells (Fig. 4A). The late differentiation marker
myogenin as well as MYH2 were also observed in Nogo-
A+ cells (Fig. 4B). Significant features of differentiated
cells included a dramatic reduction in Pax7 and increases
in MYH2 and Nogo-A (Fig. 4B). Analysis of the expres-
sion levels of Nogo-A and myogenic factors were well-
matched to these observations (Fig. 4D). During differ-
entiation, Nogo-A expression and its cytoplasmic locali-
zation corresponded to those of MYH2 (Fig. 4A, B).
Previously, we have derived iMSCs from mouse embryo
fibroblasts bearing potent myogenic differentiation capa-
city to show that iMSCs sorted according to stem cell
markers (sort-iMSCs) had enhanced myogenic potential33.
To confirm the expression of Nogo-A during myogenic
differentiation, we analyzed differentiated iMSCs and sort-
iMSCs, and observed enhanced Nogo-A expression
(Fig. 4E) and Nogo-A colocalization with MYH2 during
differentiation in both populations (Fig. 4F, G).
Predicted TF binding to Nogo-A TF-binding sites is altered
during differentiation in C2C12 cells
We analyzed the Nogo TF-binding site to generate a list
of TFs predicted to bind to the site (Table S4) and utilized
differentiated C2C12 cells to assess the participation of
predicted TFs in myoblast differentiation. Among the
predicted TFs, the expression levels of Errg, Arid3b, Arnt,
Mlxip, Klf1, and Mycn were significantly increased (Fig.
5A and Fig. S2). Further, the expression of ERRγ, a pro-
posed critical regulator of myogenesis33, was elevated in
human myopathic muscles (Fig. 5B, C). Then, we assessed
the roles of these factors in Nogo-A transcription using
small interfering RNAs (siRNAs) targeting Errg in C2C12
cells. As shown in Fig. 5D, the abrogated expression levels
of ERRγ resulted in the reduction of Nogo-A, which sug-
gests that an increase in Nogo-A expression during myo-
genesis may be regulated by the myogenic signals via ERRγ.
Nogo-A functions in myogenesis
To elucidate the role of Nogo-A during muscle differ-
entiation, Nogo-A expression in C2C12 was abrogated by
transfecting an siRNA targeting Nogo-A (si-Nogo-A),
followed by differentiation induction to evaluate Nogo-A
function during myogenesis. The Nogo-A expression level
was significantly abrogated by si-Nogo-A (growth med-
ium (GM), Fig. 6A) and was maintained during differ-
entiation medium (DM, Fig. 6A). The effect of Nogo-A
silencing by si-Nogo-A on the levels of Nogo-B, Nogo-C,
MyoD, myogenin, and MYH2 was not significant (Fig. 6A,
B). Silencing of Nogo-A significantly decreased the pro-
tein levels of Nogo-A and slightly downregulatedthe
MyoD and myogenin during differentiation (Fig. 6C, D).
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Fig. 4 Enhanced expression of Nogo-A and myogenic factors during myoblast differentiation. Cells were cultured in growth medium (GM) to
maintain a proliferation/early differentiation state; differentiation was induced by incubating cells with differentiation medium (DM) for 3 days. A, B IF
staining of Nogo-A (green) with Pax7, MyoD, myogenin, or MYH2 (red) in C2C12 mouse myoblast cells in early differentiation (A) and late
differentiation (B). Scale bar= 20 µm. C Summary of the expression levels of Nogo-A and myogenic factors during myoblast differentiation. D qRT-
PCR analysis of Nogo-A and myogenic factors in myoblasts (n= 3/group). Mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. E qRT-PCR analysis of Nogo-
A in induced muscle stem cells (iMSCs) and sorted-iMSCs (sort-iMSCs). F, G IF staining of Nogo-A (red) with Pax7 or MYH2 (green) in differentiated
iMSCs (F) and sort-iMSCs (G). Scale bar= 20 µm.
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Myotube development was attenuated by Nogo-A silen-
cing (Fig. 6E), and the decreased myotube fusion index
(Fig. 6F) and smaller-diameter myofibers (Fig. 6G, H)
indicated immature myofiber formation in the Nogo-A-
silenced cells. These results implicate the role of increased
Nogo-A in myogenesis.
Nogo-A localizes to cytoskeleton during myogenesis
As shown in Fig. 7A, mature muscles exhibited robust
expression of MYH2 and Nogo-A, which were coloca-
lized. Nogo-A belongs to the reticulon family and mainly
resides in ER; Nogo-A has a known inhibitory role in
neurite growth when it is expressed on cell membrane via
binding its receptors on oligodendrocytes14,20,21. Inter-
estingly, Nogo-A was not colocalized with calnexin,
implying that ER is not a prominent location for Nogo-A
during the growth and differentiation stages of C2C12
cells (Fig. 7B). Desmin, a muscle-specific intermediate
filament, staining was significant around the nucleus
during growth; however, differentiated C2C12 cells
exhibited stretched cytoskeletal location of desmin which
was colocalized with Nogo-A (Fig. 7C). Thus, Nogo-A
might play a role during myogenesis by interacting with
the cytoskeletal network.
Nogo-A activity in myogenesis occurs independently of its
interaction with its cognate receptor
Nogo-A activity in the plasma membrane is induced via
binding to the Nogo receptor NgR at the Nogo-66 region
and S1PR2 at the Nogo-A-specific Δ20 region34. NgR is a
common receptor bound by all three Nogo isoforms,
whereas S1PR2 is specific to Nogo-A35. Thus, we explored
the interaction between Nogo-A and S1PR2 in differ-
entiated C2C12 cells to evaluate whether Nogo partici-
pates in myoblast differentiation in a membrane receptor-
dependent manner. The expression of S1PR2 was not
altered during differentiation and its interaction with
Nogo-A was not observed in differentiated myoblasts (Fig.
S3), indicating that Nogo-A functions in an S1PR2-
independent manner in myoblast differentiation.
Fig. 5 Expression of ERRγ in differentiated C2C12 cells and dystrophic muscles, and Nogo-A expression in ERRγ-silenced C2C12 cells.
A–C qRT-PCR analysis of ERRγ during differentiation of C2C12 cells with DM (A), in normal (n= 4) and myopathic (n= 8) human muscle tissues (B),
and of muscles from WT (n= 4) andmdx (n= 4) mice (C). D qRT-PCR analysis of si-scrambled- or si-ERRγ-transfected C2C12 cells (n= 3/group). Mean
± SEM. *p < 0.05.
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Fig. 6 (See legend on next page.)
Park et al. Cell Death Discovery             (2021) 7:1 Page 9 of 18
Official journal of the Cell Death Differentiation Association
Nogo-A interacts with several proteins involved in cell
motility and cytoskeletal organization during myogenesis
Proteins common to both the cell lysates and samples
immunoprecipitated with the Nogo-A-specific antibody
were identified, and nonspecific proteins bound to the
immunoglobulin G antibody were excluded to specify
Nogo-A-interacting proteins. Finally, a list of interacting
molecules categorized according to the differentiation
state of cells was obtained by comparing Nogo-A-specific
proteins between C2C12 cells in DM and those in GM
(Table S5). The subcellular location of the listed mole-
cules varied and included extracellular matrix, plasma
(see figure on previous page)
Fig. 6 Defective myotube formation in Nogo-A-silenced C2C12 cells. Expression of Nogo-A in C2C12 myoblast was silenced using si-Nogo-A,
and myoblast differentiation was induced by DM for 3 days. A, B qRT-PCR analysis of Nogo isoforms (A) and Myod, myogenin, and Myh2 (B) in si-
scrambled- or si-Nogo-A-transfected C2C12 cells (n= 3/group). Mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. CWB of indicated proteins in Nogo-A-
silenced cells (n= 3/group). Molecular weights (kDa) are indicated. D Quantitative assessment of band intensities of WBs in C using the NIH ImageJ
software. Mean ± SEM. **p < 0.01, ***p < 0.001. E IF staining of Nogo-A (green) with DAPI (blue) in differentiated si-scrambled- or si-Nogo-A-
transfected C2C12 cells. Scale bar= 20 µm. F Fusion index of differentiated si-scrambled- or si-Nogo-A-transfected C2C12 cells. Fusion index was
calculated as the percentage of total nuclei incorporated in myotubes. G Hematoxylin/eosin staining of differentiated si-scrambled- or si-Nogo-A-
transfected C2C12 cells. Scale bar= 200 µm. H Quantitative assessment of myofiber diameter based on evaluation of 20 diameters in five fields per
group) in L. Mean ± SEM. *p < 0.05.
Fig. 7 Location of Nogo-A in mature skeletal muscle and C2C12 myoblasts, and identification of Nogo-A interacting factors during
differentiation. A–C Localization of Nogo-A in mature skeletal muscle and C2C12 myoblasts. A Isolated gastrocnemius muscles from 8-week-old
C27BL/6 mouse were sectioned and stained for Nogo-A (green) and MYH2 (red). Scale bar= 100 µm. B IF staining of Nogo-A (red) and calnexin (ER
protein, green) in growth-conditioned C2C12 cells. Scale bar= 10 µm. C IF staining of Nogo-A (red) and desmin (muscle-specific, type III intermediate
filament, green) in differentiation-conditioned C2C12 cells. Scale bar= 10 µm. D–F Expression levels of Nogo-A-interacting molecules suggested by
immunoprecipitation-mass spectrometry analysis of differentiated C2C12. qRT-PCR analysis of indicated genes in C2C12 cells cultured with DM for 2
or 4 days (D) and in muscles after 3 days or 2 weeks of notexin injury (E). F Immunoprecipitation with a Nogo-A-specific antibody was performed
using lysates of C2C12 cells maintained in GM or DM for 4 days. WB analysis of indicated proteins in immunoprecipitated samples. Molecular weights
(kDa) are indicated. G Quantitative assessment of band intensities of blots in F using the NIH ImageJ software. H Filamin-mediated cell motility
regulation and proposed model of Nogo-A’s role in muscle differentiation via its interaction with filamin-C.
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membrane, cytoskeleton, cytoplasm, ER, mitochondrion,
and nucleus. Analysis of the canonical pathways involving
the Nogo-A-binding proteins revealed a significant cor-
relation between signaling pathways regulating cell
motility and cytoskeletal organization and the Nogo-A
binding proteins (Table S6 and Fig. S4).
To elucidate the role of Nogo-A-binding proteins in
myogenesis, we selected several molecules, including
Cavin1, Cavin4, Flnc, Pdlim2, Hsp90b1, Naca, and Ybx3,
which locate to the ER or cytoskeleton. During C2C12
differentiation, the expression levels of Cavin4, Flnc,
Pdlim2, and Ybx3 were increased whereas that of Cavin1
was reduced (Fig. 7D). The levels of upregulated mole-
cules during myoblast differentiation were evaluated in
notexin-injured muscles, showing that Flnc was increased
at 3 days post injury (Fig. 7E).
Finally, we evaluated the interaction between Nogo-A
and filamin-C, the product of Flnc, during myogenesis by
Nogo-A-specific antibody-mediated immunoprecipita-
tion. C2C12 cells in DM showed significantly elevated
levels of filamin-C and Nogo-A, and the interaction
between the two proteins was enhanced compared to that
in C2C12 cells in GM (Fig. 7F, G). Insignificant alteration
of filamin-C in Nogo-A-silenced C2C12 cells (Fig. S5)
suggests that defective myogenesis of Nogo-A-silenced
cells (Fig. 6E–H) was independent with the level filamin-C
and resulted from the lack of interaction with Nogo-A.
Thus, in addition to its known role in cell motility via
binding to F-actin and vinculin in the integrin-linked
kinase (ILK) signaling pathway, our results suggest that
filamin-C also plays a role in muscle differentiation via its
interaction with Nogo-A (Fig. 7H, Fig. S4, and Table S6).
Discussion
Muscles in patients with ALS show enhanced Nogo-A
expression, suggesting that Nogo-A might be a disease
marker36. However, a link between Nogo and pathophy-
siological conditions in skeletal muscle disorders has not
yet been established.
In the present study, muscles under pathological con-
ditions including DMD and mouse myopathy models,
such as mdx, acute damage induced by myotoxic notexin
injection, and chronic muscle damage from liver dys-
function, not only showed altered expression of myogenic
factors but also consistently displayed upregulated Nogo-
A and downregulated Nogo-C (Figs. 1B and 2A, E, G).
To enhance our understanding of the role of Nogo in
muscle function, we analyzed normal and damaged
Nogo−/− muscles and found augmented inflammation
under normal conditions and defective regeneration fol-
lowing damage in the Nogo−/− muscles (Fig. 3A). Inter-
estingly, the absence of Nogo upregulated the expression
of genes involved in fat differentiation and downregulated
the expression of those modulating skeletal muscle
differentiation (Fig. 3B, D). Muscle regeneration is
essential for maintaining muscle function after damage,
and improper substitution of fat for new muscle during
muscle regeneration leads to a decline in muscle integ-
rity37. Muscle homeostasis is maintained via the regula-
tion of muscle protein metabolism38 and might be
affected by not only nutrient intake and exercise but also
circadian rhythm factors39. Circadian rhythm is regulated
via the circadian clock system located in the suprachias-
matic nucleus of anterior hypothalamus responding to
environmental stimuli, including light and diet40. Mam-
mals regulate the physiological functions of peripheral
tissues, including skeletal muscle, via the peripheral cir-
cadian clock41. Surprisingly, the Nogo−/− muscles showed
significantly altered expression of circadian clock genes
(Fig. 3F, G), but our current knowledge on the role of
Nogo in circadian clock regulation is limited. Studies
showing that Nogo-A-deficient transgenic rats have
altered circadian activity patterns suggest a role for Nogo-
A in circadian clock maintenance42. Therefore, dysregu-
lated circadian clock gene expression in Nogo−/− muscle
may lead to defective muscle homeostasis and regenera-
tion (Fig. 3). Previous analysis of the circadian tran-
scriptome in mouse skeletal muscle revealed that genes
essential for muscle function, including Myod, Atrogin-1,
and Murf-1, were subject to circadian regulation43. In
addition, Dyar et al.44 suggested the involvement of the
circadian clock in energy homeostasis and lipid metabo-
lism in skeletal muscle. CLOCK, encoded by CLOCK
(circadian locomotor output cycles kaput), and BMAL1
(brain and muscle ARNT-like 1) are major components of
the circadian machinery and regulate the expression of
other clock genes including CRY1, CYR2, PER1, and
PER2, after the formation of a heterodimer40,45. In the
present study, the Nogo−/− muscles exhibited down-
regulated levels of Clock and Bmal1, and abrogated
expression of the components of the PER/CRY complex
that inhibits the CLOCK-BAML1 complex, such as Per1,
Per2, Per3, Cry1, and Cry2 (Fig. 3F). In addition, the
expression of Bhlhe40, another inhibitor of the CLOCK-
BAML1 complex, was increased in the Nogo−/− muscles,
resulting in the upregulation in expression levels of Cebpa
and Cebpb, which participate in adipogenesis. These
results suggest that Nogo is critical in regulating circadian
rhythm and that the absence of Nogo in muscle con-
tributes to the enhanced expression of genes involved in
fat deposition in muscle tissue (Fig. 3B, D, H).
Skeletal muscle expresses all three Nogo transcript
variants, and the pathological conditions evaluated in the
present study exhibited significant increases in Nogo-A
and significant decreases in Nogo-C (Figs. 1B and 2A, E,
G). During C2C12 myoblast differentiation, the expres-
sion levels of both Nogo-A and Nogo-C were significantly
increased (Fig. 6A). Based on previous studies showing
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that Nogo-C acts as an apoptosis inducer in cardiac
muscle following myocardial infarction46, damaged mus-
cles might facilitate muscle regeneration by restricting the
pro-apoptotic function of Nogo-C.
Muscle regeneration begins with the activation of
satellite cells and results in myotube formation, which is
mediated by serial expression of myogenic factors
including Pax7, MyoD, and myogenin. Nogo-A tended to
increase in parallel with other myogenic factors in myo-
blast myocyte differentiation into myotubes (Fig. 4A–C),
and pathological conditions requiring myogenesis
induced Nogo-A expression (Figs. 1B, D and 2A, C–E, G).
Accordingly, we assessed if Nogo-A was a potent myo-
genesis regulator during muscle differentiation and found
that silenced Nogo-A resulted in attenuation of C2C12
differentiation with a minimal effect on MyoD and myo-
genin (Fig. 6).
Therefore, the levels of predicted TFs were evaluated to
determine potential regulators of Nogo-A expression, and
ERRγ showed the most significant increases during
myoblast differentiation (Fig. 5A, Table S4, and Fig. S2).
We previously reported ERRγ as a key to myogenesis33
and observed that myopathic muscles increased ERRγ
expression in the present study (Fig. 5B, C). This study
suggests the contribution of ERRγ to Nogo-A expression
in C2C12 cells by showing that silenced ERRγ down-
regulated Nogo-A expression (Fig. 5D).
We additionally uncovered that cytoskeleton is the
predominant location of Nogo-A in myogenesis (Fig. 7B,
C) and identified candidates interacting with Nogo-A
during myogenesis by immunoprecipitation-mass spec-
trometry analysis (Table S5). Filamin-C was one of the
Nogo-A interacting molecules with a known location in
the cytoskeleton and its level was significantly elevated
during C2C12 differentiation (Fig. 7D). Filamin-C is a
muscle-specific filamin, a class of actin-binding proteins,
and functions via interacting with transmembrane pro-
teins such as δ- and γ-sarcoglycan47. Mutated filamin-C
causes filaminopathy characterized by proximal muscle
weakness due to defective myofibrils and abnormally
aggregated proteins in muscle fibers48, and lack of filamin-
C results in defective myogenesis and myotube forma-
tion49. The filamin-C and Nogo-A levels were increased
during C2C12 differentiation, and the interaction between
Nogo-A and filamin-C was also enhanced (Fig. 7F, G).
Filamin-C functions via interacting with vinculin and F-
actin within the ILK signaling pathway inducing cell
motility (Fig. 7H and Table S6). Cytoskeletal reorganiza-
tion is a pivotal process for completion of myogenesis50.
The analyzed pathways associated with Nogo-A-
interacting proteins support that Nogo-A plays a role in
cellular motility and cytoskeletal organization via MYLs
(Table S6 and Fig. S4). Especially, the increased interac-
tion between Nogo-A and filamin-C during myogenesis
indicates that Nogo-A involves in myogenesis by partici-
pating in cytoskeletal rearrangement (Fig. 7H). Besides,
the defective myogenesis by the abrogation of Nogo-A
without the alteration of the filamin-C level (Fig. S5)
suggests the critical role of Nogo-A in the cytoskeletal
organization during myogenesis.
In conclusion, our findings suggest that Nogo plays a
pivotal role in maintaining muscle homeostasis by its
involvement in the modulation of lipid metabolism,
muscle cell differentiation, and circadian rhythm-related
factors. Although the role of Nogo in circadian rhythm
regulation remains elusive, our results suggest the novel
function of Nogo in regulating muscle circadian clock
genes, which might be affected by circadian rhythm
determined in the suprachiasmatic nucleus. The dysre-
gulated circadian clock appear to be contributing to
abnormal muscle homeostasis in Nogo−/− muscle. Fur-
thermore, in muscles undergoing regeneration under
pathological conditions, an increase in Nogo-A partici-
pates in the regenerative process by modulating myo-
genesis via its interaction with filamin-C.
Materials and methods
Patient samples
Skeletal muscle slices and tissue fragments were
obtained from patients at Pusan National University
Yangsan Hospital in Yangsan, Republic of Korea (Insti-
tutional Review Board No. 05-2018-045), and Yonsei
University College of Medicine in Seoul, Republic of
Korea (Institutional Review Board No. 3-2018-0060), after
obtaining approval from the Medical School Ethics
Committee. Muscle biopsies were obtained from five age-
matched healthy patients as the control group (Table 1).
Animal models
All mice were housed under appropriate conditions
with a 12 h light/12 h dark cycle and access to water ad
libitum in accordance with Kyungpook National Uni-
versity animal facility regulations. For experiments mod-
eling DMD, 12-week-old male WT (C57BL/10J) and mdx
mice (C57BL/10ScSn-Dmdmdx/J) were utilized. The mdx
mice were kindly provided by Jacques P. Tremblay
(CHUQ Research Center, Quebec City, Canada) and
C57BL/10SnSlc mice were purchased from Japan SLC
(Hamamatsu, Japan), as previously described51. Nogo−/−
mice, previously described52, were generously provided by
Binhai Zheng (University of California, San Diego, CA,
USA). Animal experiments and protocols above were
approved by the Institutional Animal Use and Care
Committee of Kyungpook National University in Daegu,
Republic of Korea (KNU 2014-0167, KNU 2018-0105),
and conformed to the policies and guidelines of the
National Institutes of Health (NIH). The intragastric (iG)
ethanol feeding model was provided by the Animal Core
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Tissue Sharing Program at the NIAAA-funded Southern
California Research Center for ALPD and Cirrhosis
(P50AA011999).
Mouse model of muscle abnormality
Notexin-induced muscle injury model
For notexin-induced muscle injury, 8-week-old male WT
(C57BL/6 J, Nogo+/+, n= 5) and Nogo KO (Nogo−/−, n= 5)
mice were intramuscularly injected with notexin (500 ng/mL
in phosphate-buffered saline (PBS); Latoxan) as a single dose
of 50 μL into the gastrocnemius muscle. Mice were killed at
8 days post injection and gastrocnemius muscles were col-
lected as previously described53.
ALD mouse model
The previously described mouse model of ALD (HCFD
+Alc+ Binge)54 includes 2 weeks of feeding with a
Western diet to produce peak fibrogenic response in liver,
1 week for iG surgery and recovery, and 8 weeks on
weekly HCFD/alcohol hybrid binges for a total of
11 weeks.
Cell culture and myogenic differentiation
C2C12 myoblast cells, an immortalized mouse myoblast
cell line, were cultured in Dulbecco’s modified Eagle’s
medium (DMEM, Corning, #10-013-CUR) supplemented
with 10% fetal bovine serum (Corning, #35-015-CU) and
100 U/mL penicillin–streptomycin (Gibo-BRL,
#15140122) in a humidified atmosphere containing 5%
CO2 at 37 °C. To induce myotube differentiation, cells
were washed with PBS and cultured with DM (DMEM
containing 2% horse serum [Gibco-BRL, #16050-122] and
100 U/mL penicillin–streptomycin). iMSCs were devel-
oped from mouse embryonic fibroblasts and sort-iMSCs
were obtained by sorting iMSCs with stem cell markers
including CD106 (Pharmingen, #01812D) and α7 integrin
(Santa Cruz, sc-50431), as previously described33.
Preparation and staining of frozen muscle tissue sections
and cells
Preparation of muscle tissue sections
Muscle tissues were fixed in 4% paraformaldehyde
(Sigma) in PBS for 24 h and immersed in gradient sucrose
solutions (30% and 35%) in PBS for 6 and 16 h, respec-
tively. To prepare muscle cryoblocks, tissues were blocked
in OCT compound (Leica, #3801480), stored at −70 °C,
sectioned into 4–5 μm slices with a Leica cryostat,
mounted on slides, and dried under room air for 30min.
Prepared sections were kept at −70 °C until staining.
Muscle paraffin blocks were prepared following dehy-
dration of the tissues with an ethanol series, embedding in
paraffin, and sectioning at 4 μm-thick slices with a Leica
rotary microtome.
Hematoxylin/eosin staining of muscle sections
Histopathologic evaluation was performed on sections
stained by routine hematoxylin/eosin staining. Cryosec-
tioned muscle tissues were rehydrated with PBS and
paraffin-embedded sections were rehydrated by immer-
sing in ethanol. After rinsing with H2O, tissues were
stained in hematoxylin solution for 5 min, washed with
H2O, and counter-stained with eosin. Mounting was fol-
lowed by dehydration with xylene and images were cap-
tured in digital format using a Leica DM5000B
microscope.
Immunofluorescence staining of muscle sections
Prepared sections were rehydrated in PBS, boiled in
10mM citric acid buffer (pH 6.0) at 95 °C for 10 min to
unmask antigens, cooled down at room temperature for
30min, washed with PBS, and permeabilized with 0.1%
Table 1 Information on patients with myopathy and normal subjects.
# Sex Age (years) Clinical diagnosis # Sex Age (years) Clinical diagnosis
D1 M 5 Inflammatory myopathy N1 F 42 Normal
D2 M 5.6 Inflammatory myopathy N2 F 26 Normal
D3 M 1.83 DMD (exon 45 deletion) N3 F 41 Normal
D4 M 5.1 Inflammatory myopathy N4 F 18 Normal
D5 M 2 Dysferlinopathy N5 F 1.5 Normal
D6 F 81 Inflammatory myopathy
D7 F 46 Inflammatory myopathy
D8 F 57 Inflammatory myopathy
D9 M 15 DMD (exon 45–52 deletion)
D10 M 20 DMD (exon 50 deletion)
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Triton-X (Sigma-Aldrich, #9002-93-1) in PBS for 5 min.
Next, the sections were blocked with 5% donkey serum in
PBS for 1 h and incubated with a cocktail primary anti-
bodies in blocking buffer for overnight at 4 °C. After
washing with PBS, a cocktail of fluorescence-conjugated
secondary antibodies (Goat anti-rabbit-IgG Alexa
Flour555-conjugated, Abcam, ab150078; Goat anti-
mouse-IgG Alexa Flour488-conjugated, Abcam,
an150114; Goat anti-mouse-IgG Alexa Fluor594-con-
jugated, Thermo Fisher, A-11005; Goat anti-rabbit-IgG
FITC-conjugated, Abcam, ab6717) were allowed to bind
for 1 h at room temperature. After washing with PBS, the
sections were mounted using antifade mounting solution
with DAPI (Cell Signaling, #8961) and images were cap-
tured using a confocal laser scanning microscope
(LSM700; Carl Zeiss).
Immunofluorescence staining of cells
After the removal of culture medium, cells were washed
with PBS and fixed with 4% paraformaldehyde for 10min.
The cells were permeabilized by incubation in ice-cold
methanol for 10 min and were washed with PBS. Next, the
cells were blocked using 5% donkey serum in PBS, incu-
bated in a cocktail of primary antibodies diluted in
blocking solution overnight at 4 °C, and incubated in a
cocktail of fluorescence-conjugated secondary antibodies
for 1 h. Coverslips were mounted with an antifade
mounting solution containing DAPI and images were
captured with a confocal laser scanning microscope.
siRNA transfection
Gene silencing was achieved by transfection of specific
siRNAs against Nogo-A and ERRγ in C2C12 myoblast
cells. siRNAs for mouse Nogo-A (si-Nogo-A) and mouse
ERRγ (si-ERR) were chemically synthesized (Bioneer,
Table 2), and premade negative control siRNA (si-
scrambled, Bioneer, SN-1011) were purchased. C2C12
cells were plated on six-well plates at 1 × 105 cells per well,
cultured to 40% confluency, and incubated with culture
medium without antibiotics for 2 h before transfection.
Lipofectamine 2000® reagent (1 : 100, Invitrogen,
#11668027) and siRNAs (50 nM) were diluted in Opti-
MEM (Thermo Fisher Scientific, #31985062) according to
the manufacturer’s instructions and the mixture was
added to culture medium for 6 h. After removing the
siRNA mixture from the culture medium, the cells were
cultured with GM for 2 days. Next, the medium was
changed to DM to induce myoblast differentiation over
3 days.
RNA isolation and quantitative PCR analysis
RNA isolation
Total RNA was isolated from cells and muscle tissues of
mice and human samples using TRIzol® reagent (Invi-
trogen), according to the manufacturer’s instructions.
Quantitative RT-PCR
cDNA was synthesized from 2 µg total RNA using
Maxima First Strand cDNA synthesis kit for RT-qPCR
(Thermo Fisher Scientific), according to the manu-
facturer’s instructions. The gene expression levels were
analyzed by quantitative reverse-transcription PCR using
SYBR Green (TOPreal qPCR premix, Enzynomics) and a
Rotor-Gene Q instrument (Qiagen) or Bio-Rad CFX
Connect Real-Time System (Bio-Rad). The expression
levels of gene transcripts were normalized to GAPDH
(human) or 18S rRNA (mouse), and the results were
evaluated by the Rotor-Gene Q series software (Qiagen)
or Bio-rad CFX Maestro (Bio-Rad).
Protein extraction and protein detection
Muscle protein extraction
Muscles from humans and mice were lysed with lysis
buffer (50 mM Tris-HCl pH 7.4, 150mM NaCl, 1 mM
EDTA, 5 mM Na3VO4, 20 mM NaF, 10 mM sodium
pyrophosphate, protease inhibitor cocktail [Roche,
#04693132001], 1 mM phenylmethylsulfonyl fluoride
(PMSF) [Generay Biotech, #0754-PMSF], 1% Triton-X,
and 0.1% SDS [Biosesang, #S2003]) and homogenized
using a homogenizer. After centrifugation (15,000 × g for
15 min at 4 °C) to remove debris, total protein con-
centration of the supernatants was determined with the
Pierce BCA protein assay kit (Thermo Scientific, #K1672).
Cell protein extraction for western blotting
Cells in 6-well plates were rinsed with PBS and lysed
with 200 µL cell lysis buffer (1× RIPA buffer [Cell Sig-
naling, #9806], 1 mM PMSF, and protease inhibitor
cocktail). The lysates were incubated at 4 °C with rocking
for 30min to facilitate protein extraction. After cen-
trifugation (15,000 × g for 15 min at 4 °C) to remove
debris, total protein concentration of the supernatants
was determined with the BCA protein assay kit.
Western blotting
Protein concentrations of the samples were adjusted to
2–3 µg/µL, which were mixed with an appropriate volume
of 5× SDS loading buffer, boiled, and electrophoresed on
Table 2 Sequences of siRNA.
Mouse siRNA Sequence (5′→3′)
Sense siRNA-ERRγ CCU CUG AUU GUA UGG AAC AUU UCU U
Antisense siRNA-ERRγ AAG AAA UGU UCC AUA CAA UCA GAG G
Sense siRNA Nogo-A CAA AGA GGA UUU AGU UUG UAG UGC A
Antisense siRNA Nogo-A UGC ACU ACA AAC UAA AUC CUC UUU G
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SDS polyacrylamide gels (10% or 12%). The separated
proteins were transferred to nitrocellulose membranes
(0.2 µm pore size; Amersham), stained with ponceau
solution (Translab, TLP-113), washed with H2O, and
incubated in blocking buffer (1% bovine serumalbumin in
Tris-buffered saline containing 0.1% Tween 20) for 1 h.
The membranes were incubated with primary antibodies
(anti-Nogo-A, Abcam, #ab62024; anti-MyoD, Santa Cruz,
#sc-32758; anti-Myogenin, Santa Cruz, #sc-12732; anti-
Pax7, Santa Cruz, #81975; anti-S1PR2, Proteintech,
#21180-a-AP) diluted to 1 : 1000 in blocking buffer over-
night at 4 °C, followed by incubation with appropriate
secondary horseradish peroxidase-conjugated antibodies
for 1.5 h. The protein levels were determined by visuali-
zation with ECL reagent (Thermo Fisher Scientific,
#34076). The bands were imaged with a chemilumines-
cence imager (Amersham) and band intensities were
analyzed using the NIH ImageJ software.
Enzyme-linked immunosorbent assay
Isolated muscles were transferred to the ProEX CETi
lysis buffer (Translab, TLP-121CETi) and homogenized
with a homogenizer, and the supernatants were collected
after centrifugation at 15,000 × g for 15 min at 4 °C. The
amount of IL-6 was measured using a Mouse IL-6 Plati-
num ELISA kit (Invitrogen, KMC0061), according to the
manufacturer’s instructions.
Immunoprecipitation with Nogo-A or S1PR2 antibody
The lysed cells in lysis buffer (500 µL/100mm culture
dish; 15 mM HEPES, 145mM NaCl, 10 mM EDTA,
0.1 mM MgCl2, 2 mM Na3VO4, 2% Triton-X, protease
inhibitor cocktail, 1 mM PMSF). The cell lysates (1000 µg
total protein) were precleared with protein A-coated
agarose beads (Cell Signaling, #9863) or protein G-coated
Dynabeads® (Invitrogen, #10003D) for 1 h at 4 °C and
immunoprecipitated with 5 µg Nogo-A antibody (Abcam,
#ab62024) or 2 µg of S1PR2 antibody (Proteintech,
#21180-a-AP) overnight at 4 °C with rotation. Immune
complexes were collected by incubation with agarose
beads Dynabeads for 3 h at 4 °C with rotation, respec-
tively. The collected beads were washed with lysis buffer
and boiled after adding 1× SDS loading buffer. Western
blotting was performed to detect Nogo-A, filamin-C, and
S1PR2 with control lysates containing 100 µg total protein
and 30 µL immunoprecipitated samples under reducing
conditions.
RNA sequencing and network analysis
mRNA sequencing and data analysis
Total RNA was isolated from the gastrocnemius muscle
tissues of Nogo+/+ and Nogo−/− mice (three biological
replicates per group) using the RNeasy mini kit (Qiagen).
mRNA was isolated from total RNA and fragmented using
the Illumina Truseq™ Stranded mRNA LT sample prep
kit, and reverse transcription of the mRNA fragments was
performed using Superscript III reverse transcriptase (Life
Technologies). Adaptor-ligated libraries were generated
according to the manufacturer’s protocol and sequenced
using a HiSeq 2500 system. To preprocess read sequence
data, adaptor sequences (TruSeq universal and indexed
adapters) were trimmed by cutadapt. The trimmed data
were aligned to the reference mouse genome (GRCm38.
p6) using the STAR aligner55 and quantified to the gene
features (GRCm38.95.gtf) in fragments per kilobase of
transcript per million fragments of mapped values
(FPKM) using the Cufflinks software.
Identification of DEGs
An expressed gene was defined as that with an FPKM ≥
1 for at least one of the six samples. For these expressed
genes, log2(FPKM) values were normalized using the
quantile normalization method56. To identify DEGs
among the expressed genes, their combined adjusted p-
values were calculated as previously described57. In brief,
for each gene, we first calculated the t-statistic using
Student’s t-test and the log2-median ratio test (log2 fold
change) by comparing log2(FPKM) values between the
Nogo+/+ and Nogo−/− samples. We then generated
empirical KO distributions of t-statistic values and log2
fold changes by randomly permuting the 6 samples 1000
times. Based on two empirical KO distributions for each
gene, we computed adjusted p-values for the Student’s t-
test and the median ratio test, and combined these
adjusted p-values using Stouffer’s method. Genes with
combined adjusted p-values < 0.05 and log2 fold changes
larger than the cutoff (absolute mean of 2.5th and 97.5th
percentile values from the empirical distribution of log2
fold changes; 1.3 fold change) were selected as DEGs.
Functional enrichment analysis
To identify cellular processes and pathways represented
by the selected DEGs, we performed enrichment analysis
of GOBPs and GOMFs, and determined KEGG pathways
using the DAVID software. The GO terms and KEGG
pathways with p-values < 0.05 were defined as being
enriched by the DEGs.
Identification of key TFs
To identify major TFs responsible for the DEGs, we first
collected TF-target information from TRED, Amadeus,
HTRIdb, MSigDB, EEDB, bZIPDB, and MetaCore™
(GeneGo, St. Joseph, MI, USA). Human TF-target rela-
tionships were converted into mouse TF-target relation-
ships using MGI human-mouse homolog mapping. Using
these TF-target relationships, we finally selected major
TFs that regulated a significant (p < 0.05) number of DEGs
(at least five) based on Fisher’s exact test.
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Network analysis
To build a network model describing the effect of Nogo
on muscular dystrophy or cell differentiation, we first
selected DEGs involved in the GOBPs and GOMFs, as
well as the KEGG pathways related to these processes. We
then collected the data on protein–protein interactions
for these selected DEGs from the following
protein–protein interactome databases: BioGrid, Con-
censusPathDB, DIP, HitPredict, IntAct, MINT, and
STRING. Using the information on the protein–protein
interactions for the selected DEGs, we constructed a
network model using Cytoscape and arranged the nodes
according to the pathway information from the KEGG
pathway database.
Immunoprecipitation-mass spectrometry analysis
Sample preparation and analysis with liquid chromatogra-
phy linked to tandem mass spectrometry
Immunoprecipitation with Nogo-A was conducted
using MS-Compatible Magnetic IP Kit (Thermo Scien-
tific, #90409). Protein concentrations of immunoprecipi-
tated samples were determined by the BCA protein assay
kit. Proteins were reduced with 10mM DL-Dithiothreitol
at 56 °C and alkylated with 50mM iodoacetamide (Sigma-
Aldrich, I1149) in the dark at room temperature. Next,
the proteins were diluted to 100 mM with ammonium
bicarbonate (Sigma, A6141), followed by the addition of
trypsin (Promega) at an enzyme:protein ratio of 1:50 and
incubation overnight at 37 °C. After digestion, the samples
were acidified with 10% trifluoroacetic acid (TFA, Pierce,
#28904), and desalted on a tC18 plate. The tC18 plate was
prepared by activation with 0.1% TFA and 80% acetoni-
trile (Macron, Avantor Performance Materials, MK-
H076-10), and equilibration with 0.1% TFA. Tryptic
peptides were loaded on the plate and washed three times
with 0.1% TFA. The peptides were eluted with 0.1% TFA
and 80% acetonitrile (ACN), and lyophilized by vacuum
centrifugation.
Approximately 1 µg of the peptides were loaded and
captured on EASY-SprayTM LC column (PepMapTM
RSLC C18, 2 µm, 100 Å, 50 µm × 15 cm) and gradient-
eluted into a Q-Exactive PLUS mass spectrometer
(Thermo Scientific) using a 40min organic gradient
(5–40% B, A= 0.1% formic acid (FA), B=ACN with 0.1%
FA). The electrospray voltage was set at 2.2 kV. The Q-
Exactive PLUS was programmed to operate in a data-
dependent mode such that the 20 most abundant pre-
cursors in each MS scan (AGC target, 3E6; maximum fill
time, 100ms; and resolution, 70 K) were subjected to
higher-energy collisional dissociation (HCD) (isolation,
1.7 Da; normalized collision energy, 27%; resolution, 7.5 K;
AGC target, 1E5; maximum injection, 50 ms, and intensity
threshold, 1.6E5). Dynamic exclusion was enabled with a
repeat count of 1 and exclusion duration of 30 s.
Processing of mass spectrometry data
Native RAW data files from the Q-Exactive PLUS mass
spectrometer were processed using Proteome Discoverer
v3.0. All data were searched against a forward-reverse
mouse database assembled from the SWISSPROT data-
base. For de-isotoped HCD spectra, the precursor mass
tolerance was set to 10 ppm and the MS/MS fragment ion
tolerance was set to 0.02 Da. Search parameters included
trypsin specificity, with a maximum of two missed clea-
vages, fixed carbamidomethylation of Cys (C,+ 57 Da),
and variable oxidation on Met (M,+ 16 Da). Reported
peptide sequences were filtered based on a 1% false
discovery rate.
The proteins identified to interact with Nogo-A were
analyzed with the ingenuity pathways analysis program
(Qiagen, https://www.qiagenbioinformatics.com/products/
ingenuity-pathway-analysis), to evaluate pathways in which
the differentiation state-specific Nogo-A-interacting pro-
teins were involved. Proteins in the proteomic data were
mapped to corresponding gene objects in the ingenuity
pathways knowledge base. Scores were derived from the p-
value of the test and indicated the likelihood of the mapped
genes in a network being found together due to random
chance (score, −log10p).
Prediction of TFs regulating Nogo expression
To predict TFs that potentially regulate Nogo expres-
sion, the TF-binding site sequence of Nogo
(ENSMUSR00000513840) was obtained from the
Ensembl database and analyzed via the JASPAR database.
Predicted factors were listed based on a relative score of
>0.9.
Statistical analysis
Statistical differences between control and experimental
samples were evaluated using unpaired Student’s t-test
(two-tailed). All results were expressed as means ± SEM.
P-values < 0.05 were considered to indicate statistical
significance.
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